The U.S. Meals and Drug Administration (FDA) has accepted PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to assist establish sufferers with epithelial...
Minimal residual illness, or MRD, testing might have the potential to supply peace of thoughts to survivors of breast most cancers, as a survivor and...
Dr. Justin Gainor, director of the Middle for Thoracic Cancers Program at Massachusetts Common Hospital, shared steering for sufferers with lung most...
The U.S. Meals and Drug Administration (FDA) has granted breakthrough remedy designation to sofetabart mipitecan for grownup sufferers with platinum-resistant epithelial ovarian,...
The U.S. Meals and Drug Administration (FDA) has accepted Guardant360 CDx as a companion diagnostic to determine sufferers with BRAF V600E-mutant metastatic...
